Chinese clinical trial and research firm Hangzhou Tigermed Consulting will start to raise at least $1 billion in its Hong Kong listing from Monday, according to two sources with direct knowledge of the matter.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
